Reported about 18 hours ago
President Trump's proposed tariffs may challenge the healthcare sector, but Eli Lilly and Novartis appear equipped to withstand the financial impact. Eli Lilly has invested significantly in U.S. manufacturing to remain insulated from tariffs, showcasing strong revenue growth and innovative products. Similarly, Novartis has pledged substantial investments in U.S. operations and continues to demonstrate solid financial performance, despite upcoming patent losses. Both companies present compelling investment opportunities within the turbulent healthcare landscape.
Source: YAHOO